Erratum

1996 ◽  
Vol 17 (6) ◽  
pp. 202-202
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hiv Infection ◽  
First Trimester ◽  
Pregnant Mother ◽  
Third Trimester ◽  
The Third ◽  
Immunodeficiency Virus

In the discussion of the "Index of Suspicion" case of human immunodeficiency virus (HIV) infection in an infant in Pediatrics in Review. 1996;17:67 (February), the sentence that reads, "Diagnosis of HIV infection in the pregnant mother should lead to her treatment with zidovudine after the third trimester...." is incorrect. It should read, "treatment with zidovudine after the first trimester."

scholarly journals Antiretroviral Therapy with a Twice-Daily Regimen Containing 400 Milligrams of Indinavir and 100 Milligrams of Ritonavir in Human Immunodeficiency Virus Type 1-Infected Women during Pregnancy

2008 ◽  
Vol 52 (4) ◽  
pp. 1542-1544 ◽  
Author(s):  
Jade Ghosn ◽  
Ines De Montgolfier ◽  
Chantal Cornélie ◽  
Stéphanie Dominguez ◽  
Claire Pérot ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Daily Regimen ◽  
Child Transmission ◽  
Third Trimester ◽  
Safety And Efficacy ◽  
Hiv Rna ◽  
The Third ◽  
Immunodeficiency Virus ◽  
Mother To Child

ABSTRACT We evaluated the safety and efficacy of a twice daily regimen containing 400 mg of indinavir and 100 mg of ritonavir in 32 human immunodeficiency virus (HIV)-infected women during pregnancy. The median indinavir trough concentration was 208 ng/ml during the third trimester. At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV.

scholarly journals Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1–Infected Women

2017 ◽  
Vol 65 (8) ◽  
pp. 1335-1341 ◽  
Author(s):  
Stein Schalkwijk ◽  
Angela Colbers ◽  
Deborah Konopnicki ◽  
Andrea Gingelmaier ◽  
John Lambert ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Third Trimester ◽  
The Third ◽  
Immunodeficiency Virus

scholarly journals Early Postpartum Pharmacokinetics of Lopinavir Initiated Intrapartum in Thai Women

2009 ◽  
Vol 53 (5) ◽  
pp. 2189-2191 ◽  
Author(s):  
Tim R. Cressey ◽  
Russell Van Dyke ◽  
Gonzague Jourdain ◽  
Thanyawee Puthanakit ◽  
Anuvat Roongpisuthipong ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Third Trimester ◽  
Serious Adverse Events ◽  
Time Curve ◽  
Thai Women ◽  
The Third ◽  
Early Postpartum Period ◽  
Concentration Time ◽  
Early Postpartum ◽  
Immunodeficiency Virus

ABSTRACT Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) μg·h/ml, 11.2 (8.0 to 17.5) μg/ml, and 4.6 (1.7 to 12.5) μg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported.

The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus

2020 ◽  
Author(s):  
Pauline Bollen ◽  
Jolien Freriksen ◽  
Deborah Konopnicki ◽  
Katharina Weizsäcker ◽  
Carmen Hidalgo Tenorio ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Pregnant Women ◽  
Geometric Mean ◽  
Polymerase Chain Reaction Test ◽  
Third Trimester ◽  
Once Daily ◽  
Antiretroviral Agents ◽  
The Third ◽  
Immunodeficiency Virus ◽  
Pharmacologically Active

Abstract Background Pharmacokinetic and efficacy data on dolutegravir in pregnant women living with human immunodeficiency virus (HIV) are still limited but needed to support its use as one of the preferred antiretroviral agents. Methods Within the multicenter Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) study, pregnant women living with HIV and using dolutegravir once daily (50 mg, with food) underwent 24-hour pharmacokinetic profiling in their third trimester and postpartum. Dolutegravir exposure in the third trimester was considered adequate if geometric mean unbound, pharmacologically active, minimal plasma concentrations (Cmin, unbound) and ≥90% of individual Cmin, unbound levels were &gt;0.85 µg/L, the proposed 90% inhibitory concentration for unbound dolutegravir. Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) for comparison of total and unbound pharmacokinetic parameters in the third trimester and postpartum were calculated, including the metabolic ratio for dolutegravir-glucuronide. Safety and virological data were collected. Results Seventeen women (76% black) were enrolled (25 evaluable pharmacokinetic profiles; 15 in the third trimester, 10 in postpartum). In the third trimester, geometric mean (coefficient of variation, %) Cmin, unbound was 2.87 (87) µg/L and 93% of individual Cmin, unbound levels were &gt;0.85 µg/L. The GMR (90% CI) in the third trimester vs postpartum was 0.86 (.68–1.10) for area under the curve (AUC0-24h), and for Cmax, 0.93 (.77–1.13). GMR (90% CI) for the trough concentrations was 0.71 (.49–1.02), based on total dolutegravir concentrations. Four serious adverse events were reported, unlikely related to dolutegravir. The HIV polymerase chain reaction test was negative in 14/17 infants (result unknown for 3 infants). Conclusions Pharmacokinetic changes for dolutegravir in late pregnancy are not clinically relevant and support the use of dolutegravir 50 mg once daily with food in pregnancy. Clinical Trials Registration NCT00825929.

scholarly journals Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network

2020 ◽  
Vol 71 (10) ◽  
pp. e714-e717 ◽  
Author(s):  
Vera Bukkems ◽  
Coca Necsoi ◽  
Carmen Hidalgo Tenorio ◽  
Coral Garcia ◽  
Jürgen Rockstroh ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Clinical Trials ◽  
Pregnant Women ◽  
Effective Concentration ◽  
Third Trimester ◽  
Dosing Interval ◽  
The Third ◽  
Immunodeficiency Virus ◽  
Clinically Significant

Abstract This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929.

Human Immunodeficiency Virus (HIV) Infection in Children

1987 ◽  
Vol 1 (3) ◽  
pp. 381-395 ◽  
Author(s):  
Beverly Ryan ◽  
Edward Connor ◽  
Anthony Minnefor ◽  
Frank Desposito ◽  
James Oleske
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hiv Infection ◽  
Immunodeficiency Virus

Correlations Between the Values of Maternal Glycemia from the Last Trimester of Pregnancy and Fetal Birth Weight

2013 ◽  
Vol 20 (3) ◽  
pp. 259-265
Author(s):  
Monica Vereş ◽  
Aurel Babeş ◽  
Szidonia Lacziko
Keyword(s):  
First Trimester ◽  
Mean Value ◽  
Fetal Macrosomia ◽  
Entire Group ◽  
Third Trimester ◽  
The Third ◽  
Group I ◽  
Fetal Birth Weight ◽  
First Trimester Of Pregnancy ◽  
The Mean

Abstract Background and aims: Gestational diabetes represents a form of diabetes diagnosed during pregnancy that is not clearly overt diabetes. In the last trimester of gestation the growth of fetoplacental unit takes place, thus maternal hyperglycemia will determine an increased transplacental passage, hyperinsulinemia and fetal macrosomia. The aim of our study was that o analyzing the effect of maternal glycemia from the last trimester of pregnancy over fetal weight. Material and method: We run an observational study on a group of 46 pregnant women taken into evidence from the first trimester of pregnancy, separated in two groups according to blood glucose determined in the third trimester (before birth): group I normoglycemic and group II with hyperglycemia (>92mg/dl). Results: The mean value of third trimester glycemia for the entire group was of 87.13±22.03. The mean value of the glycemia determined in the third trimester of pregnancy was higher in the second group (109.17 mg/dl) in comparison to the first group (74.,21 mg/dl). The ROC curve for third trimester glycemia as fetal macrosomia appreciation test has an AUC of 0.517. Conclusions: Glycemia determined in the last trimester of pregnancy cannot be used alone as the predictive factor for fetal macrosomia.

Sign in / Sign up

Export Citation Format

Share Document